Why insider trading matters?

When insiders buy shares on the open market, this can thus be regarded as a strong endorsement by those that know the company the best -- they are literally betting their own money on the company's future. Insider selling, however, is not necessarily meaningful in any way, as there is a range of reasons for insiders to liquidate (some) of the shares they own.

- Seeking Alpha
PDL BIOPHARMA, INC. (PDLI)
Sector: Healthcare; Industry: Biotechnology

PDL BioPharma, Inc. acquires, manages, and commercializes commercial stage pharmaceutical assets and late clinical stage pharmaceutical products in North America, Europe, Asia, and internationally. The company operates through Medical Devices, Strategic Positions, Pharmaceutical, and Income Generating Assets segments. The Pharmaceutical segment manufactures, markets, and sells prescription medicine products for the treatment of hypertension to wholesalers under the Tekturna and Tekturna HCT names in the United States, as well as under the Rasilez and Rasilez HCT names internationally. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006.

PDLI Symbol Info by TradingView

Trade Date Insider Title Buy/Sell #Shares Price Value Option
2019-06-10 PDL BIOPHARMA, INC. 10%-Owner Buy 6,666,667 $4.50 $30,000,002 Yes

Insider Smart

Enphase Energy, Inc (ENPH) - ENPH was $10+ in 15Q1 then dropped to $2 and eventually went under $1. From 15Q4 to 17Q4 it built a 2-year-long base then BOOM! Stock went as high as $70 and likely will make a new high. Catch one or two moves like this you can retire early. One hint before the big move was that CEO and CFO were constantly accumulating, this kind of information is priceless.

Insider Smart

Altimmune, Inc. (ALT) - Venrock Healthcare Capital Partners III, L.P., 10%-owner of ALT bought 1.3M shares in late May then added another 1.5M shares in June with an averaged ~$8 per share. 10 days after the accumulation, ALT price jumped to $10.